{"nctId":"NCT03801707","briefTitle":"Utilization of Hepatitis C Positive Kidneys in Negative Recipients","startDateStruct":{"date":"2019-03-22","type":"ACTUAL"},"conditions":["Kidney Transplant","Hepatitis C","HCV"],"count":54,"armGroups":[{"label":"Intervention group","type":"EXPERIMENTAL","interventionNames":["Drug: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]","Drug: Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]"]}],"interventions":[{"name":"Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]","otherNames":["Epclusa"]},{"name":"Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]","otherNames":["Mavyret"]}],"eligibilityModule":{"eligibilityCriteria":"Recipient Inclusion/Exclusion Criteria:\n\nInclusion Criteria:\n\n* Adult age \\>18 years able to provide consent\n* Lack of available living donor\n* Calculated pre-transplant reactive panel (cPRA) of \\<80%\n* Estimated post-transplant survival (EPTS) index \\>20% and \\<80%\n* Negative pre-transplant human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) serology and blood HCV polymerase chain reaction (PCR)\n* No clinically significant pre-transplant liver disease\n\nExclusion Criteria:\n\n* Living donor available\n* Dialysis time \\>5 years\n* Listing for multi-organ transplantation\n* Active or recent history (\\<6 months) of alcohol abuse or substance abuse\n* Clinically significant liver disease as determined by principal investigator\n* History of hepatocarcinoma\n* Pregnancy or lactation\n* Refusal to accept blood transfusion\n* HIV infection\n* HCV pcr or antibody positive\n* HBV infection\n\nDonor Inclusion Criteria:\n\n* Positive HCV PCR at time of donation\n* Kidney donor profile index (KDPI)\\<85%","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Patients With Undetectable Hepatitis C Virus (HCV) Polymerase Chain Reaction (PCR) at 12 Weeks After Completion of HCV Treatment","description":"Proportion of patients with undetectable hepatitis C virus (HCV) polymerase chain reaction (PCR) at 12 weeks after completion of HCV treatment was to test the efficacy of the treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]}]},{"type":"PRIMARY","title":"Elevation in Liver Enzyme >5 Times the Upper Limits, Development of Acute Cholestatic Hepatitis , or Intolerance to Direct Acting Antiviral Therapies","description":"Elevation in liver enzyme \\>5 times the upper limits, development of acute cholestatic hepatitis , or intolerance to Direct acting antiviral therapies was to test the safety of utilizing HepC positive kidneys for transplant.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Glomerular Filtration Rate (eGFR) at 6 and 12 Months Post-transplant","description":"Estimated glomerular filtration rate (eGFR) at 6 and 12 months post-transplant was to test the safety of utilizing of HepC positive kidneys.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient's Survival at 6 and 12 Months","description":"Patient's survival at 6 and 12 months measuring safety of utilizing of HepC positive kidneys.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Graft Survival at 6 and 12 Months","description":"Graft survival at 6 and 12 months measuring safety of utilizing HepC positive kidneys.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Liver enzyme elevation"]}}}